bluuebunny/crossref_metadata_2025_split huggingface dataset:
P6251Prognostic value of ACEi/ARBS in elderly patients with heart failure with reduced ejection fraction with and without chronic kidney disease
Authors: Martinez Milla J , Cortes M , Lopez-Castillo M , Devesa A , Rivero-Monteagudo A L , Martin-Mariscal M , Briongos S , Taibo M , Franco-Pelaez J A , Tunon J 
Published: October 2019

Abstract

Introduction
Angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers therapy (ACEI/ARB) have shown to reduce mortality in patients with heart failure and reduced left ventricular ejection fraction (HFrEF). However, there is lack of information about the benefit of these drugs in patients with chronic kidney disease (CKD), and even less in elderly patients. Our aim is to compare the prognostic impact of ACE/ARB if CKD is present or not

Methods
From January 2008 to July 2014, we consecutively enlisted 802 patients aged >75 years that had ejection fraction ≤35%. Clinical, echocardiographic and ECG data were taken from hospital records. Follow-up was made via telephone and hospital records as well. We analyzed the relationship between treatment with ACEi/ARBs (with different doses) and occurrence of mortality or MACE (major adverse cardiovascular events: composite of death from any cause or hospitalization for heart failure).

Results
From the total population 410 (51%) patients that had not CKD (glomerular filtration rate (GFR) >60ml/min/1,73m2) and 390 (49%) patients had CKD (with GFR ≤60ml/min/1,73m2). We analyze the population according the presence or not of CKD. Both groups had similar characteristics except the age: 81.5±4.5 years vs. 82.6±4.1 (p<0.05) and the percentage of use of ACEi/ARB 78.8% of the total vs 66.9% of the total (p<0.05). The mean ejection fraction was 27.9±6.5% vs 28.12±6.5% (p>0.05). The mean follow up was 33±22 vs 32±23 months (p>0.05). In patients with no CKD 170 (42%) patients died and 239 (58%) patients had a MACE. In the CKD group 211 (54.1%)patients died and 257 (65.9%)patients had a major cardiovascular event. In the univariate analysis in both groups the use of ACEi/ARB reduced the mortality and the MACE. After a multivariate analysis ACEi/ARB appear to be beneficial in the CKD group (OR 0.71 [0.50–0.98]) but not in no CKD group

Conclusions
According to our data, treatment with ACEI/ARB in elderly patients HFrEF and CKD should be encouraged even more than in those without CKD.
P6255Impact of whole grain consumption on arterial stiffness. Results of the Corinthian cross-sectional survey
Authors: Vavouranaki G , Oikonomou E , Vogiatzi G , Lazaros G , Tsalamandris S , Siasos G , Chasikidis C , Theofilis P , Mistakidi C V , Anastasiou M , Galiastatos N , Santouri M , Tousoulis D 
Published: October 2019

Abstract

Introduction
The benefits of certain dietary patterns on cardiovascular diseases has been questioned over the last years. Whole grain consumption has been one of the controversial issues regarding the effect on cardiovascular disease. In Greek rural population consumptions of bread is part of the daily meal and a possible source of whole grain.

Purpose
To investigated the effect of whole grain bread consumption on arterial stiffness in Mediterranean population.

Methods
In a cross-sectional survey (Corinthia study) volunteers subjects completed a food frequency questioner (FFQ), including a question of consumption of bread on regular basis, whole grain (group I) or not (group II). Medical history, lifestyle habits, anthropometric and vital signs, as well as, laboratory blood test were performed. All patients underwent carotid-femoral pulse wave velocity (C-F PWV) measurements which were obtained noninvasively by SphygmoCor devise.

Results
Among the 2043 volunteers 1389 patients had adequate quality of pulse wave velocity recordings and were regular consumers of bread. Whole grain bread was consumed by 473 subjects (male 37%, female 63%,) but 916 (male 43.1%, female 56.9%) did not consume. Subjects consuming whole grain bread were younger compare to those who were not (group I: 62±11 years vs. group II: 64±12 years, p=0.02), have lower C-F PWV (group I: 9.04±2.93 m/sec vs. group II: 9.57±2.76 m/sec, p=0.01) but no other statistical difference were observe among other parameters (i.e. hypertension, diabetes mellitus, BMI, smoking etc). Hierarchical multiple regression showed that whole grain consumption predicted pulse wave velocity statistically significantly (b=−0.33, 95% CI: −0.62, −0.17, p=0.03) in addition to age (b=0.09, 95% CI 0.08–0.10, p<0.001), systolic blood pressure (b=0.02, 95% CI 0.01, 0.03, p<0.001) beta=0.157) and diabetes mellitus (b=0.75, 95% CI 0.40, 1.09, p<0.001).

Conclusion
Whole grain bread consumption has a beneficial effect on arterial stiffness as detected by better carotid femoral pulse wave velocity. This may have a positively effect on cardiovascular diseases.
P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease
Authors: Marx N , McGuire D K , Johansen O , Rosenstock J , Kahn S E , Cooper M E , Toto R , Wanner C , Pfarr E , Schnaidt S Y , George J T , Von Eynatten M , Perkovic V , Zinman B , Alexander J A 
Published: October 2019

Abstract

Background/Introduction
CARMELINA was a randomized placebo-controlled clinical trial designed to demonstrate the cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes (T2D) and concomitant cardiorenal disease. Despite a particularly elevated CV risk, only limited long-term evidence from randomized controlled trials for safety and efficacy of glucose lowering medications is available for this population.

Purpose
To characterize the effects of linagliptin on net CV disease and hospitalization burden in this population.

Methods
People with T2D and either i) urine albumin creatinine ratio (UACR) >30 mg/g with concomitant CV disease, or ii) estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2 regardless of UACR, or eGFR ≥45–75 mL/min/1.73m2 and UACR >200 mg/g, were randomized to linagliptin 5 mg or placebo q.d. in a double-blind fashion in addition to standard of care. We assessed the effects of linagliptin versus placebo on all first plus recurrent CV events and all-cause hospitalizations using a using a negative binomial model to account for within-subject correlation.

Results
A total of 6979 participants were enrolled (mean age 66 years, 63% male, eGFR 54.6 ml/min/1.73m2, median UACR 162 mg/g, 59% with history of ischemic heart disease, 27% with history of heart failure (HF)) and followed for a median of 2.2 years. Adding recurrent events increased the number of events for analysis from 5.3–57.5% across CV/HF outcomes and 112.4% for hospitalizations. In analyses of first plus recurrent events, the event rate ratio (95% CI) with linagliptin versus placebo was 0.98 (0.82, 1.16; p=0.78) for 3-point MACE, 1.03 (0.79, 1.35; p=0.83) for myocardial infarction 1.03 (0.83, 1.29; p=0.77) for myocardial infarction plus revascularization, 0.89 (0.65, 1.22; p=0.48) for stroke, 0.94 (0.70, 1.27; p=0.69) for stroke plus TIA, 0.94 (0.75, 1.20; p=0.63) for hospitalized HF, 0.92 (0.77, 1.11; p=0.40) for the composite of CV death or hospitalized HF, and 0.96 (0.87, 1.06; p=0.40) for all-cause hospitalization (Figure).

Conclusion
Linagliptin showed similar risk of either first or recurrent CV or hospitalization events compared with placebo in patients with T2D and cardiorenal disease. These data support the CV safety of linagliptin and, considering the high volume of recurrent events, underscores the significant CV disease burden experienced by patients with T2D and cardiorenal disease

Acknowledgement/Funding
Boehringer Ingelheim and Eli Lilly
P6301Pro-inflammatory intermediate monocytes relate to right ventricular pressure in heart failure of adult congenital heart disease
Authors: Wienecke L M , Fraccarollo D , Galuppo P , Treptau J , Kockelmann F , Bauersachs J , Westhoff-Bleck M 
Published: October 2019

Abstract

Background
Heart failure (HF) is a leading cause of mortality in adults with congenital heart disease (ACHD). ACHD is characterized by predominant right heart disease. In non-congenital heart disease inflammation and its mediators such as monocytes/macrophages play an important pathophysiological role in HF. We aimed to evaluate the role of circulating monocyte subsets in ACHD-HF.

Methods
This cross-sectional study includes 209 ACHD outpatients (mean age: 35.3±11.0 years; NYHA class I/II/III-IV 58.3%/19.6%/13%; male: 59.8%) and 21 healthy controls (age: 29.8±12.6 years; male: 47.6%). Patients with clinical signs of infection, inflammatory diseases or malignancies were excluded. Multivariate analysis was used to relate blood monocyte subsets to NYHA class and echocardiographically derived parameters of right and left ventricular function.

Results
Compared to control, ACHD had significantly higher circulating levels of pro-inflammatory HLA-DR+CD14++CD16+ intermediate monocytes (24.0±3.3 vs. 43.6±1.7 cells/μL; p<0.001).
NT-proBNP was independently associated with reduced left (p<0.0001) and right (p<0.001) ventricular function, diastolic dysfunction (p=0.04) and vena cava diameter (p=0.02).
Independent predictors of NYHA class were intermediate monocytes (p=0.022), plasma noradrenaline (p=0.002), albumin (p=0.001) and NT-proBNP (p<0.001). Elevated right ventricular systolic pressure (>35 mmHg) was independently associated with both, higher intermediate monocyte counts (OR 1.36; 95% CI: 1.13–1.62; p=0.001) and low oxygen saturation (OR 0.8; 95% CI: 0.7–0.92; p=0.001), even after multivariable adjustment for age, sex and NYHA class.

Conclusions
Right ventricular pressure and oxygen saturation are linked to elevated intermediate monocytes, suggesting an important link between inflammation and HF in ACHD. Circulating blood intermediate monocytes represent a promising biomarker in ACHD.

Acknowledgement/Funding
German Heart Foundation (Deutsche Herzstiftung e.V.)
P6312Pregnancy outcomes in women with cardiothoracic transplants: a systematic review and meta-analysis
Authors: Dong S , D'Souza R , Acuna S , Zaffar N , Bhagra C , Silversides C , Ross H 
Published: October 2019

Abstract

Background
Increasing numbers of women with heart-lung transplants (HLT) are now planning and continuing with pregnancies. The risks of pregnancies in these women have not been systematically assessed.

Methods
A search strategy was designed for MEDLINE, EMBASE, and Cochrane Central from inception to January 2018 to identify studies reporting outcomes in three or more pregnancies following HLT. Pooled incidence of maternal outcomes and fetal and neonatal outcomes were calculated using random-effects meta-analysis and reported per 100 pregnancies with 95% confidence intervals (CI). Risk-of-bias was determined using the Joanna Briggs Checklist for Case Series. Subgroup analysis was conducted based on transplanted organ.

Results
A total of 3658 records were identified, 172 full texts reviewed, and 12 studies included. The included studies reported on 385 pregnancies in 272 transplant recipients. Maternal complications included mortality during pregnancy [0.5% (0, 1.1%)], mortality during the specified follow-up period [15.4% (10,4, 20.3%)], graft rejection during pregnancy [7.4% (4.2, 10.5%)], preeclampsia [12.3% (7.2%, 17.5%)], gestational diabetes [6.4% (2.6, 10.1%)], and caesarean deliveries [41.4% (33.4, 48.7%)]. As many as 78.4% (69.8, 86.9%) pregnancies resulted in live births. Of the remainder, 13.6% (6.3, 20.9%) resulted in miscarriages (fetal loss under 20 weeks of gestation), 2% (0.3, 3.7%) resulted in stillbirths (fetal loss after 20 weeks of gestation), and 6.8% (4.3, 9.3%) in pregnancy terminations for various reasons. Of those born live, 3.4% (1.3, 5.6%) succumbed in the neonatal period. Over half the pregnancies [51.2% (31, 71.3%)] resulted in preterm deliveries (<37 weeks of gestation). There were subgroup-specific variations in the prevalence of complications. For example, lung transplant recipients were less likely than heart transplant recipients to have pregnancies complicated by preeclampsia [8.3% (3.0, 13.6%) vs. 17.8% (10.8, 24.8%)] suffer maternal mortality during the follow up period [41.4% (23.4, 59.3%) vs. 10.8% (5.9, 15.8%)]. Studies had a moderate risk-of-bias.

Conclusions
Although large proportions of pregnancies in women with HLT result in live births and few maternal deaths occur during pregnancy, these women are at increased risk for preeclampsia, preterm birth, perinatal mortality and maternal mortality following childbirth. Subgroup-specific variations should be taken into account while counselling HLT recipients contemplating pregnancies.

Acknowledgement/Funding
None
P6318Survival rate in patients with the identification of predictors for antibody mediated rejection
Authors: Tkhal L , Kosmacheva E , Pashkova I 
Published: October 2019

Abstract

Introduction
Antibody mediated rejection (AMR) is still an important issue in heart transplantation (HT). The standard methods of diagnosis and treatment remain controversial, whereas immunosuppressive therapy is mainly used to prevent cellular rejection.

Purpose
To determine predictors of AMR using the routine investigations in clinical practice.

Methods
During 7 years we conducted a single center study of 181 HT recipients. Patients were divided into 5 groups based on AMR and detected anti-HLA, such as DSA and non-DSA antibodies. Recipients underwent immunology screening and HLA antibodies tests, DSA; 2D-speckle-tracking echocardiography using the Kruskal-Wallis and Wilcoxon signed-rank tests; Spearman correlation, the table of critical values for the Pearson correlation. Kaplan-Meier curves were used to estimate the survival rate. Roc-analysis was used to measure the diagnostic accuracy. Statistical analysis was performed with the STATISTICA 10 (Tibco, USA).

Results
The study demonstrated the lowest survival in patients with anti-HLA antibodies, such as anti-HLA and non-DSA antibodies versus recipients without anti-HLA de novo. Survival in patients with DSA is 40%, and in patients without DSA is 68%. It should be noted that comparing of survival in patients with HLA identified in different post-transplant period showed that patients with HLA-antibodies identified in late post-transplant period had worse survival (50%) than recipients who developed antibodies in the early post-transplant period (75%). On the second stage of the study we conducted 2D-speckle-tracking echocardiography. At first we estimated 2D-STE parameters for the selected groups of patients in the first period of our study, and then during AMR and the late period of the study. AMR effectively reduces the parameters of deformation and mechanics, GLPS LV,%i = −9,94±1,37, RadS LV,% 19,36±3,66, Cir SLV,% −17,83±4,89, ROT APEX°,4,51±1,46, ROT BASE°, −4,75±2,12, ROT MID° 1,94±1,41, TWIST,% 8,90±1,85, RV-FWS,% −15,89±0,89. The possible criteria for diagnosis of AMR include global peak systolic strain, sensitivity (S) 86,2%, specificity (Sp) 90,4%, radial systolic strain, S 75,8%, Sp 84,5% circular systolic strain, S 78,6%, Sp 84,4%; left ventricular twist S 66,7%, Sp 94,2% (p<0,001).

Conclusions
There is a correlation between changes and parameters of 2D-speckle-tracking echocardiography. DSA limits the survival and increases the risk for AMR.
P6319CT derived fractional flow reserve (FFRct) for functional coronary artery evaluation in the follow-up of patients after heart transplantation
Authors: Budde R P J , Nous F M A , Constantinescu A A , Nieman K , Koweek L M , Leipsic J , Manintveld O C 
Published: October 2019

Abstract

Background
Cardiac allograft vasculopathy (CAV) remains a leading cause of morbidity and mortality after heart transplantation. Annual screening is recommended to improve risk stratification and early treatment of CAV and is often performed with invasive coronary angiography (ICA). Coronary computed tomography angiography (CCTA) with CCTA-derived fractional flow reserve (FFRct) might be a non-invasive alternative to ICA for the surveillance of CAV providing both anatomical and functional information.

Purpose
To describe our initial results with CCTA and FFRct for detection of CAV in a cohort of heart transplant patients.

Methods
Heart transplant patients who underwent CCTA with FFRct as part of routine annual assessment for CAV were enrolled in a prospective registry from February 2018 to February 2019 in a single center. The most recently known CAV score (0–3) based on invasive angio and single photon emission computed tomography (SPECT) before CCTA was recorded. CCTA image quality was scored as non-diagnostic, moderate, good or excellent. FFRct analysis was performed off-site by a commercial company. For each coronary stenosis >30%, an FFRCTvalue distal to the stenosis was measured. For the RCA, LAD and CX without a stenosis, the FFRct value in the most distal location in the vessel was recorded. CAV classification was rescored based on CCTA. Demographics, additional diagnostic tests, and treatment plans were evaluated including major adverse events (MACE) during 90-day follow-up.

Results
65 patients (56 (39–65) years (median/ 25th–75thpercentile), 40% women) that were 11 (7–16) years after transplantation were included. The most recent CAV score was 0 in 52 patients (80%) and 1 or 2 in 13 patients. CCTA image quality was good or excellent in 59 (91%) patients. CCTA reclassified CAV scores in 32 (49%) patients to 33 patients with CAV 0, 18 patients with CAV 1, 9 patients with CAV 2 and 5 patients with CAV 3. In 17 patients (26%) at least one stenosis with FFRct ≤0.80 was detected including 11 patients with single vessel disease, 5 with two-vessel disease and one with three-vessel disease. In the 48 patients without a focal stenosis, mean distal FFRct values were 0.88 (0.86–0.91), 0.87 (0.85–0.90) and 0.90 (0.86–0.91) at less than 10, 10–15 or more than 15 years after transplantation, respectively (p=0.457). Additional tests were performed in 10 (15%) patients (1 SPECT and 10 invasive coronary angiographies), which resulted in revascularization by PCI in 6 (9%) patients. No MACE occurred during 90-day follow-up.

Conclusion
CCTA with FFRct can be successfully performed in heart transplant patients, detects patients with significant coronary stenosis and CCTA leads to substantial reclassification of CAV grades.

Acknowledgement/Funding
FFRct analysis was performed as part of the ADVANCE registry which is supported by Heartflow Inc.
P6320Unilateral phrenic nerve stimulation improves functional capabilities in heart failure patients
Authors: Potratz M , Gutleben K J , Rudolph V , Fox H 
Published: October 2019

Abstract

Introduction
Central sleep apnea is highly common in heart failure (HF) patients and often appears as Cheyne-Stokes-respiration (CSR). Presence of CSR in HF has been clearly shown to connote worse prognosis and HF patients with CSR experience increased mortality. Since widely used adaptive servoventilation is now contraindicated in HF with reduced ejection fraction alternative approaches for CSR treatment are needed. Unilateral phrenic nerve stimulation (PNS) is a novel technique to treat CSR and has recently been demonstrated to be safe and effective in HF patients, resulting in its market approval. While PNS has been shown to sufficiently treat CSR nothing is known in regard to functional characteristics in PNS treated HF patients. Therefore, this study investigated standardized six-minute walk test (6MWT) before and during PNS treatment in HF patients assessing functional impact of PNS on HF.

Methods
We prospectively enrolled 25 HF patients that have been implanted with novel PNS, mean age 67.05±11.22 years, 88% male, showing effective PNS CSR treatment. Adjacent to determine PNS effectiveness on CSR treatment standardized 6MWT was conducted before, at 6 months and at 12 months after PNS implantation.

Results
25 (100%) patients had CSR, introduced PNS significantly suppressed respiratory events from 118.33±96.35 before to 34.65±51.41 after PNS therapy onset (p=0.001). Regarding functional improvements 6MWT improved from initial 369.5±163.56 meters before PNS implantation to 410±169.71 meters after 12 months. Hereby, total walking distance increased by 49.5% ± 100.8% (p=0.035).

Conclusion
PNS treatment is not only a novel technique to allow CSR treatment in HF, but for the first time, we provide comprehensible data illustrating functional improvements in HF in 6MWT, implying significant enhancements in daily physical capability of HF CSR patients treated with PN.
P6324Contribution of muscle efficiency in heart failure patients post phase 2 cardiac rehabilitation
Authors: Sa Mendes G , Durazzo A , Moreno L , Santos S , Neto M , Mendes M 
Published: October 2019

Abstract

Background
Muscle efficiency (ME), can help explain the observed improvement in patients without increase in oxygen uptake (VO2) after cardiac rehabilitation programme (CRP). The better use of energy, independent to the oxygen delivery to muscle, may improve the functional capacity in Heart failure (HF) patients. Our aim was to evaluate the contribution of muscle efficiency improvement after CR on functional capacity.

Methods
We analyse consecutive patients data that had their phase 2 CR concluded, with HF as admission indication with no medical therapy changes and CRT implantation during this period. The aetiology of HF and biometric data, functional class, BNP, Minnesotta and EuroQol questionnaires and cardiorespiratory test pre and post 4 months of CRP were collected. The average of the exercise load in the first two and last two training sessions were recorded. ME was calculated at peak exercise during cardiopulmonary exercise test in pre and post CRP (see formula above).

Results
From 55 HF patients sequentially admitted in our CRP, during the last 24 months, 45 were included, since 2 were transplanted, 1 died and the 7 didn't concluded the program or not had all the data mentioned in the methods. The mean age was 60,5±10,3 years and 78% were male. Ischemic aetiology with depressed ejection fraction (64%) was the main admission indication, followed by cardiomyopathies (18%). Betablockers, ACEi or ARBs or ARNi and MRA were taken in 91%, 93%, 46%, respectively. ICD and CRT were previously implanted in 44% of the patients. Comparing pre and post CRP VO2 at peak exercise and aerobic threshold levels no statically differences were found. In this cohort 27 (60%) patients increased ME. At the end of the CRP, this group had a higher improvement in METs (p=0,021), higher gain in lean mass (p=0,041), in EuroQoL (p=0,002) and in physical dimension of Minnesotta questionnaire (p=0,032), when compared with patients that didn't improve the ME in at least 5%. In 22 patients that increased ME, the VO2 at aerobic threshold level didn't improve by at least 5% and in this group the same benefits were confirmed.
Formula of Muscle Efficiency

Conclusions
The improvement in exercise load reached in the post CRP cardiopulmonary test, independently of possible cardiac output changes (VO2 peak), seems to be explained in part by the increase in ME improvement.